treatment options for dlbcl patients who relapse after car-t cell therapy
Published 1 year ago • 329 plays • Length 1:55Download video MP4
Download video MP3
Similar videos
-
2:14
treatment options for patients with dlbcl who relapse after car-t therapy
-
5:24
treatment strategies for patients with dlbcl who relapse after car-t therapy
-
0:44
emerging options for patients with dlbcl who relapse after car-t therapy
-
1:20
limitations of car t-cell therapy for dlbcl
-
2:38
approaching the treatment of patients with lbcl who relapse after bispecific antibodies
-
0:32
enhancing outcomes of patients with dlbcl treated with car t-cell therapy
-
1:39
managing early & late relapse after first-line therapy for dlbcl
-
6:54
the future of car-t therapy in the management of dlbcl
-
2:10
new algorithm for second-line dlbcl: the role of car-t therapy
-
2:05
strategies to implement car-t in dlbcl
-
2:49
exploring available third-line treatment options for r/r dlbcl: car-t, bispecifics, adcs & mabs
-
3:43
safety and efficacy of ytb323, a car t-cell therapy, in r/r dlbcl
-
2:38
car-t therapy for aggressive b-cell lymphomas
-
3:52
updates on the use of car-t therapy for the treatment of dlbcl in the second-line setting
-
3:21
safety management of car-t cell therapy in dlbcl
-
0:51
the value of car-t cell therapy in r/r dlbcl
-
2:31
car t-cell therapy toxicities in b-cell lymphomas
-
2:17
the role of car t-cell therapy for treating myeloma in the era of bispecific antibodies
-
7:40
immunotherapy for aml and all: checkpoint inhibitors & car t-cells for b-cell all